Lineage Cell Therapeutics : FORM S-3-Registration Statements -March 10, 2024 at 04:43 am EDT

As filed with the Securities and Exchange Commission on March 7, 2024


Registration No. 333-


UNITED STATES


SECURITIES...

Related Keywords

United States ,Washington ,California ,State Of California ,Tel Aviv ,Israel ,American ,Georgea Samuel ,Brianm Culley , ,Exchange Commission ,Roche Group ,Roche Ltd ,Lineage Cell Therapeutics Inc ,Genentech Inc ,Implications Of Beinga Smaller Reporting Company ,Exchange Commission On ,California Institute For Regenerative Medicine ,Tel Aviv Stock Exchange ,Genentech ,Eterna Therapeutics Inc ,Securities Exchange ,Cell Therapeutics ,Securities Act ,Exchange Act ,Certain Information ,Can Find More Information ,Lineage Cell Therapeutics ,License Agreement ,California Institute ,Investigational New Drug ,Oligodendrocyte Progenitor Cells ,Spinal Cord Injury ,Novel Device ,Smaller Reporting Company ,Securities Exchange Act ,Sarbanes Oxley Act ,Capital Stock Common Shares ,Capital Stock Preferred Shares ,Debt Securities ,Annual Report ,Financial Condition ,Quarterly Report ,